Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 3Gynecologic 2Gastrointestinal 2Breast 1

Conditions

Leukemia, Myeloid, Acute 35Recurrence 27Multiple Myeloma 27Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Non-Hodgkin 25Lymphoma 20Neoplasms 16Lymphoma, Large B-Cell, Diffuse 16Lymphoma, B-Cell 15Lymphoma, Follicular 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Mantle-Cell 13Leukemia 13Carcinoma, Non-Small-Cell Lung 13Stomach Neoplasms 11Ovarian Neoplasms 9Pancreatic Neoplasms 8Neoplasm Metastasis 8Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Myelodysplastic Syndromes 6Melanoma 6Lymphoma, B-Cell, Marginal Zone 6Breast Neoplasms 6Liposarcoma, Myxoid 5Colorectal Neoplasms 5Burkitt Lymphoma 5

Interventions

Pemetrexed 13Cisplatin 12Nivolumab 5Carboplatin 5pembrolizumab 4Ipilimumab 4Cyclophosphamide 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3fludarabine 3defactinib 3amatuximab 2Paclitaxel 2Gemcitabine 2Drug Therapy 2tremelimumab 1tazemetostat 1osimertinib 1napabucasin 1enzalutamide 1bemcentinib 1abemaciclib 1VS-5584 1Trabectedin 1Thiostrepton 1Safety 1Panobinostat 1Monatide (IMS 3015) 1Midazolam 1Letrozole 1LY3023414 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Mesothelioma, Malignant × fludarabine × Clear all
NCT07510815 2026-04-06

DUAL-MESO-NK

Beijing Biotech

Phase 1/2 Recruiting
36 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
6 enrolled
BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡